Clinical TrialAug 10, 2026, 07:02 AM
Veru Fully Enrolls PLATEAU Trial; Secures Enobosarm Patent to 2044
AI Summary
Veru Inc. announced the full enrollment of its Phase 2b PLATEAU clinical trial for enobosarm and semaglutide, with interim results expected in Q1 2027. The company also received a USPTO notice of allowance for a key U.S. patent for enobosarm, extending protection until at least October 2044. Financially, Veru reported a decreased net loss for Q3 2026 to $7.0 million and for the nine months ended June 30, 2026, to $15.1 million, alongside an increase in cash reserves.
Key Highlights
- Phase 2b PLATEAU clinical trial for enobosarm and semaglutide fully enrolled with 239 patients.
- Interim analysis results for the PLATEAU trial are on track for calendar Q1 2027.
- Received USPTO notice of allowance for a key U.S. patent for enobosarm, providing protection until at least October 2044.
- Net loss for Q3 2026 decreased to $7.0 million ($0.30 per share) from $7.3 million ($0.50 per share) in Q3 2025.
- Net loss for YTD 2026 decreased to $15.1 million ($0.68 per share) from $24.2 million ($1.65 per share) in YTD 2025.
- Cash, cash equivalents, and restricted cash increased to $23.9 million as of June 30, 2026, from $15.8 million as of September 30, 2025.
- Research and development expenses increased to $4.4 million in Q3 2026 from $3.0 million in Q3 2025.
Price Impact
More from VERU
Business Update1d ago, 8:26 AM
Veru Inc. Advances Sabizabulin for Pancreatic Cancer; Discontinues Inflammation Program
Quarterly ResultAug 10, 8:58 AM
VERU Reports Q3 Net Loss of $7.0M; Raises Going Concern Doubt
Quarterly ResultAug 10, 6:32 AM
Veru Q3 Net Loss $7.0M; Enobosarm Trial Fully Enrolled; Patent Until 2044